[Effect of vasopressor agents on the vessel wall].
D000804:Angiotensin II / Q000494:pharmacology; D000818:Animals; D001794:Blood Pressure; D001798:Blood Proteins; D001808:Blood Vessels / Q000187:drug effects*; D002339:Carotid Arteries / Q000187:drug effects; D002415:Cats; D004285:Dogs; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004837:Epinephrine / Q000494:pharmacology; D005938:Glucocorticoids / Q000494:pharmacology; D006168:Guinea Pigs; D006614:Hindlimb / Q000098:blood supply; D006973:Hypertension / Q000503:physiopathology; D006977:Hypertension, Renal / Q000503:physiopathology; D007668:Kidney / Q000503:physiopathology; D008901:Mineralocorticoids / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D011453:Prostaglandins / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D012039:Regional Blood Flow / Q000187:drug effects; D012171:Retinal Vessels / Q000187:drug effects; D012501:Saphenous Vein / Q000187:drug effects; D012701:Serotonin / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000494:pharmacology*; D014667:Vasopressins / Q000502:physiology
D001798:Blood Proteins; D005938:Glucocorticoids; D008901:Mineralocorticoids; D011453:Prostaglandins; D014662:Vasoconstrictor Agents; D014667:Vasopressins; D000804:Angiotensin II; D012701:Serotonin; D009638:Norepinephrine; D004837:Epinephrine
Wirkung vasopressorischer Substanzen auf die Gefässwand